Compounds > bay 60-7550
Page last updated: 2024-10-15

bay 60-7550

Cross-References

ID SourceID
PubMed CID135564787
CHEMBL ID370962
SCHEMBL ID2232786
SCHEMBL ID18380627
SCHEMBL ID19205847
MeSH IDM0579878

Synonyms (34)

Synonym
HY-14992
2-(3,4-dimethoxy-benzyl)-7-[(r)-1-((r)-1-hydroxy-ethyl)-4-phenyl-butyl]-5-methyl-3h-imidazo[5,1-f][1,2,4]triazin-4-one
bdbm50166893
CHEMBL370962 ,
bay-60-7550
2-(3,4-dimethoxybenzyl)-7-[(2r,3r)-2-hydroxy-6-phenylhexan-3-yl]-5-methylimidazo[5,1-f][1,2,4]triazin-4(3h)-one
19F ,
bay60-7550
bay 60-7550
439083-90-6
2-[(3,4-dimethoxyphenyl)methyl]-7-[(1r)-1-[(1r)-1-hydroxyethyl]-4-phenylbutyl]-5-methyl-imidazo[5,1-f][1,2,4]triazin-4(1h)-one
4HTX
CS-0279
gtpl5147
2-[(3,4-dimethoxyphenyl)methyl]-7-[(2r,3r)-2-hydroxy-6-phenylhexan-3-yl]-5-methyl-1h-imidazo[5,1-f][1,2,4]triazin-4-one
bay607550
zrn7lzk9tq ,
bay-607550
imidazo(5,1-f)(1,2,4)triazin-4(1h)-one, 2-((3,4-dimethoxyphenyl)methyl)-7-((1r)-1-((1r)-1-hydroxyethyl)-4-phenylbutyl)-5-methyl-
unii-zrn7lzk9tq
2-(3,4-dimethoxybenzyl)-7-((2r,3r)-2-hydroxy-6-phenylhexan-3-yl)-5-methylimidazo[5,1-f][1,2,4]triazin-4(3h)-one
SCHEMBL2232786
DTXSID50649549
2-[(3,4-dimethoxyphenyl)methyl]-7-[(2r,3r)-2-hydroxy-6-phenylhexan-3-yl]-5-methylimidazo[5,1-f][1,2,4]triazin-4(1h)-one
SCHEMBL18380627
AKOS027323749
SCHEMBL19205847
2-(3,4-dimethoxybenzyl)-7-((2r,3r)-2-hydroxy-6-phenylhexan-3-yl)-5-methylimidazo[1,5-f][1,2,4]triazin-4(3h)-one
BCP14349
Q15634074
C90482
MS-28842
2-[(3,4-dimethoxyphenyl)methyl]-7-[(2r,3r)-2-hydroxy-6-phenylhexan-3-yl]-5-methyl-3h-imidazo[5,1-f][1,2,4]triazin-4-one
Z3244812827
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)IC50 (µMol)0.00320.00001.77679.2000AID1440951; AID1449241; AID1449315; AID1458534; AID1458938; AID1480122; AID1574952; AID1574977; AID1625364; AID240759
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (25)

Processvia Protein(s)Taxonomy
heart valve developmentcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
ventricular septum developmentcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
aorta developmentcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwaycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of cGMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cAMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to macrophage colony-stimulating factor stimuluscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of vascular permeabilitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of vascular permeabilitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of cAMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP catabolic processcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of inflammatory responsecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
establishment of endothelial barriercGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to mechanical stimuluscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to cAMPcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to cGMPcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to transforming growth factor beta stimuluscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to 2,3,7,8-tetrachlorodibenzodioxinecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of gene expressioncGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of cGMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of cAMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of mitochondrion organizationcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (11)

Processvia Protein(s)Taxonomy
magnesium ion bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP-stimulated cyclic-nucleotide phosphodiesterase activitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
protein bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
zinc ion bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cAMP bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
TPR domain bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
phosphate ion bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
protein homodimerization activitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
plasma membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
nucleuscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytoplasmcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial outer membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial inner membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
endoplasmic reticulumcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
Golgi apparatuscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytosolcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
plasma membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
presynaptic membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
perinuclear region of cytoplasmcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
nucleuscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial inner membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
perinuclear region of cytoplasmcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial outer membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
synaptic membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytosolcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial matrixcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (70)

Assay IDTitleYearJournalArticle
AID1440951Inhibition of PDE2a (unknown origin) using cAMP as substrate after 30 mins by Scintillation proximity assay2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Design and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders.
AID1449249Selectivity ratio of IC50 for PDE9A1 (unknown origin) to IC50 for full length recombinant human FLAG-tagged PDE2A3 expressed in sf21 cells2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.
AID1625364Inhibition of human His-tagged PDE2A catalytic domain (578 to 919 residues) expressed in Escherichia coli BL21-CodonPlus(DE3) cells using cGMP as substrate by HTRF assay2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
AID1058015Selectivity ratio of IC50 for PDE (unknown origin) to IC50 for porcine/bovine heart myocardium PDE22013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
PDE2 inhibition: potential for the treatment of cognitive disorders.
AID1449242Selectivity ratio of IC50 for PDE1B1 (unknown origin) to IC50 for full length recombinant human FLAG-tagged PDE2A3 expressed in sf21 cells2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.
AID1449247Selectivity ratio of IC50 for PDE7B (unknown origin) to IC50 for full length recombinant human FLAG-tagged PDE2A3 expressed in sf21 cells2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.
AID1330516Inhibition of PDE1 (unknown origin)2017ACS medicinal chemistry letters, Jan-12, Volume: 8, Issue:1
Potential Treatment of Cognitive Impairment in Schizophrenia by Phosphodiesterase 2 (PDE2) Inhibitors.
AID1058017Inhibition of pig/bovine heart myocardium PDE2 after 15 mins by scintillation proximity assay in presence of [3H]-cAMP2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
PDE2 inhibition: potential for the treatment of cognitive disorders.
AID1480123Intrinsic clearance in human hepatocytes assessed per million cells at 1 uM after 0.5 to 4 hrs by HPLC-HRMS method2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Lead Diversification at the Nanomole Scale Using Liver Microsomes and Quantitative Nuclear Magnetic Resonance Spectroscopy: Application to Phosphodiesterase 2 Inhibitors.
AID1458938Inhibition of PDE2A (unknown origin) using [3H]cGMP as substrate after 30 mins by scintillation proximity assay2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor
AID1480155Drug level in dog liver microsomes treated with 2-(3,4-dimethoxybenzyl)-7-((2R,3R)-2-hydroxy-6-phenylhexan-3-yl)-5-methylimidazo[1,5-f][1,2,4]triazin-4(3H)-one at 20 uM after 1 hr by UHPLC-UV-HRMS method2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Lead Diversification at the Nanomole Scale Using Liver Microsomes and Quantitative Nuclear Magnetic Resonance Spectroscopy: Application to Phosphodiesterase 2 Inhibitors.
AID1596293Inhibition of recombinant N-terminal-GST-Th-tagged full length human PDE2A1 expressed in Sf9 cells using FAM-cAMP as substrate at 1xIC50 incubated for 60 mins by fluorescence plate reader analysis2019European journal of medicinal chemistry, Jul-15, Volume: 174InCl
AID1574966Inhibition of PDE2 in mouse HT22 cells assessed as suppression of corticosterone-induced decrease in cAMP level at 1 uM after 24 hrs by ELISA2019Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3
Design, synthesis of novel purin-6-one derivatives as phosphodiesterase 2 (PDE2) inhibitors: The neuroprotective and anxiolytic-like effects.
AID1458534Inhibition of PDE2A (unknown origin)2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders.
AID1872559Drug concentration in brain of Wistar rat at 10 mg/kg, po measured after 240 mins2022European journal of medicinal chemistry, Mar-15, Volume: 232Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.
AID1596270Inhibition of recombinant N-terminal-GST-Th-tagged full length human PDE2A1 expressed in Sf9 cells using FAM-cAMP as substrate at 0.1xIC50 incubated for 60 mins by fluorescence plate reader analysis2019European journal of medicinal chemistry, Jul-15, Volume: 174InCl
AID1480153Drug metabolism in dog liver microsomes assessed as 7-((2R,3R)-2,6-Dihydroxy-6-phenylhexan-3-yl)-2-(3,4-dimethoxybenzyl)-5-methylimidazo[5,1-f][1,2,4]triazin-4(3H)-one diastereomer 2 formation at 20 uM after 1 hr by UHPLC-UV-HRMS method2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Lead Diversification at the Nanomole Scale Using Liver Microsomes and Quantitative Nuclear Magnetic Resonance Spectroscopy: Application to Phosphodiesterase 2 Inhibitors.
AID1449251Selectivity ratio of IC50 for PDE11A4 (unknown origin) to IC50 for full length recombinant human FLAG-tagged PDE2A3 expressed in sf21 cells2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.
AID1330524Inhibition of PDE9A (unknown origin)2017ACS medicinal chemistry letters, Jan-12, Volume: 8, Issue:1
Potential Treatment of Cognitive Impairment in Schizophrenia by Phosphodiesterase 2 (PDE2) Inhibitors.
AID1458537Selectivity ratio of IC50 for PDE1C (unknown origin) to IC50 for PDE2A (unknown origin)2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders.
AID1449248Selectivity ratio of IC50 for PDE8B (unknown origin) to IC50 for full length recombinant human FLAG-tagged PDE2A3 expressed in sf21 cells2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.
AID1449244Selectivity ratio of IC50 for PDE4D3 (unknown origin) to IC50 for full length recombinant human FLAG-tagged PDE2A3 expressed in sf21 cells2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.
AID240759Inhibition of human phosphodiesterase 22005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.
AID1596290Inhibition of recombinant N-terminal GST tagged full length human PDE1B expressed in Sf9 cells using FAM-cAMP as substrate at 1xIC50 incubated for 60 mins by fluorescence plate reader analysis2019European journal of medicinal chemistry, Jul-15, Volume: 174InCl
AID1480122Inhibition of human PDE2A1 using 3',5'-[3H]cGMP as substrate after 30 mins by scintillation proximity assay2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Lead Diversification at the Nanomole Scale Using Liver Microsomes and Quantitative Nuclear Magnetic Resonance Spectroscopy: Application to Phosphodiesterase 2 Inhibitors.
AID1449250Selectivity ratio of IC50 for PDE10A1 (unknown origin) to IC50 for full length recombinant human FLAG-tagged PDE2A3 expressed in sf21 cells2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.
AID1330525Inhibition of PDE10A (unknown origin)2017ACS medicinal chemistry letters, Jan-12, Volume: 8, Issue:1
Potential Treatment of Cognitive Impairment in Schizophrenia by Phosphodiesterase 2 (PDE2) Inhibitors.
AID1368377Inhibition of PDE2 (unknown origin)2018Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1
Discovery of novel purine nucleoside derivatives as phosphodiesterase 2 (PDE2) inhibitors: Structure-based virtual screening, optimization and biological evaluation.
AID1330521Inhibition of PDE5 (unknown origin)2017ACS medicinal chemistry letters, Jan-12, Volume: 8, Issue:1
Potential Treatment of Cognitive Impairment in Schizophrenia by Phosphodiesterase 2 (PDE2) Inhibitors.
AID1449243Selectivity ratio of IC50 for PDE3A1 (unknown origin) to IC50 for full length recombinant human FLAG-tagged PDE2A3 expressed in sf21 cells2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.
AID1330526Inhibition of PDE11A (unknown origin)2017ACS medicinal chemistry letters, Jan-12, Volume: 8, Issue:1
Potential Treatment of Cognitive Impairment in Schizophrenia by Phosphodiesterase 2 (PDE2) Inhibitors.
AID1449315Inhibition of PDE2A (unknown origin)2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.
AID1480154Drug metabolism in dog liver microsomes assessed as 2-(3,4-Dimethoxybenzyl)-7-((2R,3R)-2-hydroxy-6-oxo-6-phenylhexan-3-yl)-5-methylimidazo[5,1-f ][1,2,4]triazin-4(3H)-one formation at 20 uM after 1 hr by UHPLC-UV-HRMS method2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Lead Diversification at the Nanomole Scale Using Liver Microsomes and Quantitative Nuclear Magnetic Resonance Spectroscopy: Application to Phosphodiesterase 2 Inhibitors.
AID1574969Anxiolytic activity in ICR mouse model of chronic stress-induced cognitive impairment assessed as increase in time spent in open arms at 0.5 mg/kg, ip measured for 5 mins test period by elevated plus maze test2019Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3
Design, synthesis of novel purin-6-one derivatives as phosphodiesterase 2 (PDE2) inhibitors: The neuroprotective and anxiolytic-like effects.
AID1480152Drug metabolism in dog liver microsomes assessed as 7-((2R,3R)-2,6-Dihydroxy-6-phenylhexan-3-yl)-2-(3,4-dimethoxybenzyl)-5-methylimidazo[5,1-f][1,2,4]triazin-4(3H)-one diastereomer 1 formation at 20 uM after 1 hr by UHPLC-UV-HRMS method2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Lead Diversification at the Nanomole Scale Using Liver Microsomes and Quantitative Nuclear Magnetic Resonance Spectroscopy: Application to Phosphodiesterase 2 Inhibitors.
AID1574965Inhibition of PDE2 in mouse HT22 cells assessed as suppression of corticosterone-induced decrease in cGMP level at 1 uM after 24 hrs by ELISA2019Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3
Design, synthesis of novel purin-6-one derivatives as phosphodiesterase 2 (PDE2) inhibitors: The neuroprotective and anxiolytic-like effects.
AID1480151Drug metabolism in dog liver microsomes assessed as 7-((2R,3R)-2,6-Dihydroxy-6-phenylhexan-3-yl)-2-(4-hydroxy-3-methoxybenzyl)-5-methylimidazo[5,1-f][1,2,4]triazin-4(3H)-one formation at 20 uM after 1 hr by UHPLC-UV-HRMS method2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Lead Diversification at the Nanomole Scale Using Liver Microsomes and Quantitative Nuclear Magnetic Resonance Spectroscopy: Application to Phosphodiesterase 2 Inhibitors.
AID1596267Inhibition of recombinant N-terminal GST-tagged full-length human PDE1A1 expressed in Sf9 cells using FAM-cAMP as substrate at 0.1xIC50 incubated for 60 mins by fluorescence plate reader analysis2019European journal of medicinal chemistry, Jul-15, Volume: 174InCl
AID1058016Selectivity ratio of IC50 for porcine/bovine PDE1C to IC50 for porcine/bovine heart myocardium PDE22013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
PDE2 inhibition: potential for the treatment of cognitive disorders.
AID1330518Inhibition of human PDE2 using FAM-labeled cAMP as substrate after 60 mins in presence of cGMP by florescence polarization assay2017ACS medicinal chemistry letters, Jan-12, Volume: 8, Issue:1
Potential Treatment of Cognitive Impairment in Schizophrenia by Phosphodiesterase 2 (PDE2) Inhibitors.
AID1480149Drug metabolism in dog liver microsomes assessed as 2-(3,4-Dimethoxybenzyl)-5-methyl-7-((2R,3R)-2,5,6-trihydroxy-6-phenylhexan-3-yl)imidazo[5,1-f ][1,2,4]triazin-4(3H)-one formation at 20 uM after 1 hr by UHPLC-UV-HRMS method2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Lead Diversification at the Nanomole Scale Using Liver Microsomes and Quantitative Nuclear Magnetic Resonance Spectroscopy: Application to Phosphodiesterase 2 Inhibitors.
AID1596291Inhibition of recombinant N-terminal GST tagged human PDE1C (2 to 634 aa) expressed in Sf9 cells at 1xIC50 using FAM-cAMP as substrate incubated for 60 mins by fluorescence plate reader analysis2019European journal of medicinal chemistry, Jul-15, Volume: 174InCl
AID1164384Plasma concentration in rat at 10 mg/kg, po after 30 mins2014ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9
Structure-Based Design of a Potent, Selective, and Brain Penetrating PDE2 Inhibitor with Demonstrated Target Engagement.
AID1458939Selectivity ratio of IC50 for pig arota PDE1C to IC50 for PDE2A (unknown origin)2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor
AID1330520Inhibition of PDE4B (unknown origin)2017ACS medicinal chemistry letters, Jan-12, Volume: 8, Issue:1
Potential Treatment of Cognitive Impairment in Schizophrenia by Phosphodiesterase 2 (PDE2) Inhibitors.
AID1164385Drug level in rat brain at 10 mg/kg, po after 30 mins2014ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9
Structure-Based Design of a Potent, Selective, and Brain Penetrating PDE2 Inhibitor with Demonstrated Target Engagement.
AID1480150Drug metabolism in dog liver microsomes assessed as 7-((2R,3R)-2,6-Dihydroxy-6-phenylhexan-3-yl)-2-(4-methoxy-3-hydroxybenzyl)-5-methylimidazo[5,1-f][1,2,4]triazin-4(3H)-one formation at 20 uM after 1 hr by UHPLC-UV-HRMS method2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Lead Diversification at the Nanomole Scale Using Liver Microsomes and Quantitative Nuclear Magnetic Resonance Spectroscopy: Application to Phosphodiesterase 2 Inhibitors.
AID1596314Inhibition of recombinant N-terminal GST tagged human PDE1C (2 to 634 aa) expressed in Sf9 cells at 10xIC50 using FAM-cAMP as substrate incubated for 60 mins by fluorescence plate reader analysis2019European journal of medicinal chemistry, Jul-15, Volume: 174InCl
AID1449245Selectivity ratio of IC50 for bovine PDE5A1 to IC50 for full length recombinant human FLAG-tagged PDE2A3 expressed in sf21 cells2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.
AID1449253Half life in rat liver microsomes2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.
AID1872558Displacement of [3H]-cAMP from PDE2 derived form bovine heart incubated for 15 mins by scintillation counting method2022European journal of medicinal chemistry, Mar-15, Volume: 232Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.
AID1449252Apparent intrinsic clearance in human liver microsomes2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.
AID1164383Ratio of drug level in brain to plasma in rat at 10 mg/kg, po after 30 mins2014ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9
Structure-Based Design of a Potent, Selective, and Brain Penetrating PDE2 Inhibitor with Demonstrated Target Engagement.
AID1330519Inhibition of PDE3B (unknown origin)2017ACS medicinal chemistry letters, Jan-12, Volume: 8, Issue:1
Potential Treatment of Cognitive Impairment in Schizophrenia by Phosphodiesterase 2 (PDE2) Inhibitors.
AID1480124Apparent permeability across RRCK cells after 1.5 hrs2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Lead Diversification at the Nanomole Scale Using Liver Microsomes and Quantitative Nuclear Magnetic Resonance Spectroscopy: Application to Phosphodiesterase 2 Inhibitors.
AID1449241Inhibition of full length recombinant human FLAG-tagged PDE2A3 expressed in sf21 cells using [3H]cGMP as substrate by scintillation proximity assay2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.
AID1596289Inhibition of recombinant N-terminal GST-tagged full-length human PDE1A1 expressed in Sf9 cells using FAM-cAMP as substrate at 1xIC50 incubated for 60 mins by fluorescence plate reader analysis2019European journal of medicinal chemistry, Jul-15, Volume: 174InCl
AID1574977Inhibition of PDE2 (unknown origin) using [3H]cAMP as substrate measured after 30 mins by scintillation proximity assay2019Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3
Design, synthesis of novel purin-6-one derivatives as phosphodiesterase 2 (PDE2) inhibitors: The neuroprotective and anxiolytic-like effects.
AID1574952Inhibition of PDE2 (unknown origin) using [3H]cAMP or [3H]cGMP as substrate measured after 30 mins by liquid scintillation counting method2019Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3
Design, synthesis of novel purin-6-one derivatives as phosphodiesterase 2 (PDE2) inhibitors: The neuroprotective and anxiolytic-like effects.
AID1330523Inhibition of PDE8A (unknown origin)2017ACS medicinal chemistry letters, Jan-12, Volume: 8, Issue:1
Potential Treatment of Cognitive Impairment in Schizophrenia by Phosphodiesterase 2 (PDE2) Inhibitors.
AID1449254Substrate activity at MDR1 (unknown origin) assessed as efflux ratio of permeability from basolateral to apical side over apical to basolateral side by cell based assay2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.
AID1330522Inhibition of PDE7B (unknown origin)2017ACS medicinal chemistry letters, Jan-12, Volume: 8, Issue:1
Potential Treatment of Cognitive Impairment in Schizophrenia by Phosphodiesterase 2 (PDE2) Inhibitors.
AID1449246Selectivity ratio of IC50 for bovine PDE6 to IC50 for full length recombinant human FLAG-tagged PDE2A3 expressed in sf21 cells2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.
AID1440952Selectivity ratio of IC50 for PDE1c (unknown origin) to IC50 for PDE2a (unknown origin)2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Design and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders.
AID1596312Inhibition of recombinant N-terminal GST tagged full length human PDE1B expressed in Sf9 cells using FAM-cAMP as substrate at 10xIC50 incubated for 60 mins by fluorescence plate reader analysis2019European journal of medicinal chemistry, Jul-15, Volume: 174InCl
AID1596311Inhibition of recombinant N-terminal GST-tagged full-length human PDE1A1 expressed in Sf9 cells using FAM-cAMP as substrate at 10xIC50 incubated for 60 mins by fluorescence plate reader analysis2019European journal of medicinal chemistry, Jul-15, Volume: 174InCl
AID1596269Inhibition of recombinant N-terminal GST tagged human PDE1C (2 to 634 aa) expressed in Sf9 cells at 0.1xIC50 using FAM-cAMP as substrate incubated for 60 mins by fluorescence plate reader analysis2019European journal of medicinal chemistry, Jul-15, Volume: 174InCl
AID1596268Inhibition of recombinant N-terminal GST tagged full length human PDE1B expressed in Sf9 cells using FAM-cAMP as substrate at 0.1xIC50 incubated for 60 mins by fluorescence plate reader analysis2019European journal of medicinal chemistry, Jul-15, Volume: 174InCl
AID1596315Inhibition of recombinant N-terminal-GST-Th-tagged full length human PDE2A1 expressed in Sf9 cells using FAM-cAMP as substrate at 10xIC50 incubated for 60 mins by fluorescence plate reader analysis2019European journal of medicinal chemistry, Jul-15, Volume: 174InCl
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2013Journal of the American Chemical Society, Aug-14, Volume: 135, Issue:32
X-ray crystal structure of phosphodiesterase 2 in complex with a highly selective, nanomolar inhibitor reveals a binding-induced pocket important for selectivity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (6.67)29.6817
2010's13 (86.67)24.3611
2020's1 (6.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
cilostamide
cilostamide: selective inhibitor of cyclic AMP phosphodiesterase & platelet aggregation; structure		3.5820quinolines
cilostazol
[no description available]		3.5110lactam;
tetrazoles		anticoagulant;
bronchodilator agent;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
fibrin modulating drug;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent
diazepam
Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.		2.21101,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
dipyridamole
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752). dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.		3.5820piperidines;
pyrimidopyrimidine;
tertiary amino compound;
tetrol		adenosine phosphodiesterase inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
1-methyl-3-isobutylxanthine
1-Methyl-3-isobutylxanthine: A potent cyclic nucleotide phosphodiesterase inhibitor; due to this action, the compound increases cyclic AMP and cyclic GMP in tissue and thereby activates CYCLIC NUCLEOTIDE-REGULATED PROTEIN KINASES. 3-isobutyl-1-methylxanthine : An oxopurine that is xanthine which is substituted at positions 1 and 3 by methyl and isobutyl groups, respectively.		3.56203-isobutyl-1-methylxanthine
milrinone
[no description available]		3.1210bipyridines;
nitrile;
pyridone		cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
papaverine
Papaverine: An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.. papaverine : A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.		2.5720benzylisoquinoline alkaloid;
dimethoxybenzene;
isoquinolines		antispasmodic drug;
vasodilator agent
pentoxifylline
[no description available]		2.1310oxopurine
phenobarbital
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.		2.2110barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative
rolipram
[no description available]		4.6440pyrrolidin-2-onesantidepressant;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
zardaverine
zardaverine: structure given in first source. zardaverine : A pyridazinone derivative in which pyridazin-3(2H)-one is substituted at C-6 with a 4-(difluoromethoxy)-3-methoxyphenyl group. It is a phosphodiesterase inhibitor, selective for PDE3 and 4.		2.1310organofluorine compound;
pyridazinone		anti-asthmatic drug;
bronchodilator agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
peripheral nervous system drug
papaverine hydrochloride
[no description available]		3.5110
2-chloroadenosine
5-chloroformycin A: structure given in first source		2.1710purine nucleoside
5-nitroquinoline
[no description available]		2.1310
2-amino-4,6-dimethyl pyrimidine
2-amino-4,6-dimethyl pyrimidine: structure in first source		2.1310aminopyrimidine
cladribine
[no description available]		2.1710organochlorine compound;
purine 2'-deoxyribonucleoside		antineoplastic agent;
immunosuppressive agent
5-nitroindazole
[no description available]		2.1310
7-chloro-4-hydroxyquinoline
7-chloro-4-hydroxyquinoline: structure given in first source		2.1310
fingolimod
fingolimod : An aminodiol that consists of propane-1,3-diol having amino and 2-(4-octylphenyl)ethyl substituents at the 2-position. It is a sphingosine 1-phosphate receptor modulator used for the treatment of relapsing-remitting multiple sclerosis. A prodrug, fingolimod is phosphorylated by sphingosine kinase to active metabolite fingolimod-phosphate, a structural analogue of sphingosine 1-phosphate.		2.2110aminodiol;
primary amino compound		antineoplastic agent;
CB1 receptor antagonist;
immunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist
tadalafil
[no description available]		4.120benzodioxoles;
pyrazinopyridoindole		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
clofarabine
[no description available]		2.1710adenosines;
organofluorine compound		antimetabolite;
antineoplastic agent
methotrexate
[no description available]		2.2110dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
9-(2-hydroxy-3-nonyl)adenine
(2R,3S)-EHNA : EHNA of absolute configuration 2R,3S. Selective inhibitor of cGMP-stimulated phosphodiesterase (PDE2) (IC50 = 0.8 - 4 mM). Also a potent inhibitor of adenosine deaminase.		3.5620EHNAEC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor
9-(2-hydroxy-3-nonyl)adenine
(2S,3R)-EHNA : EHNA of absolute configuration 2S,3R.		2.5920EHNA
cilomilast
[no description available]		3.5620methoxybenzenes
rp 73401
piclamilast: an antiasthmatic agent and phosphodiesterase 4 inhibitor; structure in first source. piclamilast : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 3-(cyclopentyloxy)-4-methoxybenzoic acid with the primary amino group of 3,5-dichloropyridin-4-amine.		2.1310aromatic ether;
benzamides;
chloropyridine;
monocarboxylic acid amide		anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
phosphodiesterase IV inhibitor
2-amino-4-methyl-3-nitropyridine
[no description available]		2.1310
vinpocetine
vinpocetine: whole issue of Arzneim Forsch (23 articles) discuss this drug; Arzneim Forsch 26(10a);1976; RN given refers to parent cpd with unspecified isomeric designation		4.120alkaloidgeroprotector
rolipram
(-)-rolipram : The (R)-enantiomer of rolipram.		2.1310rolipram
mesopram
mesopram: a potent & selective type IV phosphodiesterase inhibitor		2.1310
roflumilast
[no description available]		4.6440aromatic ether;
benzamides;
chloropyridine;
cyclopropanes;
organofluorine compound		anti-asthmatic drug;
phosphodiesterase IV inhibitor
cyclic nucleotide phosphodiesterases, type 4
[no description available]		2.1310
3-(n,n-dimethylsulfonamido)-4-methyl-nitrobenzene
BRL-50481 : A C-nitro compound that is benzene substituted by N,N-dimethylaminosulfonyl, methyl and nitro groups at positions 1, 2 and 5, respectively. It is a phosphodiesterase inhibitor selective for the PDE7 subtype (Ki = 180 nM).		3.7820C-nitro compound;
sulfonamide;
toluenes		bone density conservation agent;
EC 3.1.4.53 (3',5'-cyclic-AMP phosphodiesterase) inhibitor;
geroprotector
baohuoside i
baohuoside I: structure given in first source; isolated from the herb Epimedium davidii		2.1310glycosyloxyflavoneanti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
plant metabolite
rs 25344
RS 25344: inhibits phosphodiesterase PDE-4D3; structure given in first source		2.1310
apremilast
[no description available]		2.2110aromatic ether;
N-acetylarylamine;
phthalimides;
sulfone		non-steroidal anti-inflammatory drug;
phosphodiesterase IV inhibitor
pf-2545920
[no description available]		3.5110
(2R,3S)-EHNA hydrochloride
(2R,3S)-EHNA hydrochloride : A hydrochloride salt obtained by reaction of (2R,3S)-EHNA with one equivalent of hydrochloric acid. Selective inhibitor of cGMP-stimulated phosphodiesterase (PDE2) (IC50 = 0.8 - 4 mM). Also a potent inhibitor of adenosine deaminase.		3.5110hydrochlorideEC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor
sildenafil
sildenafil : A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position.		4.430piperazines;
pyrazolopyrimidine;
sulfonamide		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
zaprinast
zaprinast: anaphylaxis inhibitor; structure		4.120triazolopyrimidines
vardenafil
vardenafil : The sulfonamide resulting from formal condensation of the sulfo group of 4-ethoxy-3-(5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one-2-yl)benzenesulfonic acid and the secondary amino group of 4-ethylpiperazine.		3.1210imidazotriazine;
N-alkylpiperazine;
N-sulfonylpiperazine		EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
2-methyl-4(3h)-quinazolinone
2-methyl-4(3H)-quinazolinone: from Bacillus cereus; structure given in first source		2.1310
4-hydroxyquinazoline
4-oxo-3,4-dihydroquinazoline: structure in first source		2.1310quinazolines
sildenafil citrate
Sildenafil Citrate: A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.. sildenafil citrate : The citrate salt of sildenafil.		2.2110citrate saltEC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
bay 73-6691
BAY 73-6691: potent and selective inhibitor of phosphodiesterase 9; structure in first source		2.5720
6-((3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-1-(tetrahydro-2h-pyran-4-yl)-1,5-dihydro-4h-pyrazolo(3,4-d)pyrimidin-4-one
[no description available]		3.5110
ConditionIndicatedRelationship StrengthStudiesTrials
Cognition Disorders
Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.		03.7330
Age-Related Memory Disorders
[description not available]		02.1510
Memory Disorders
Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.		02.1510
Polyarthritis
[description not available]		02.2110
Allergic Encephalomyelitis
[description not available]		02.2110
MS (Multiple Sclerosis)
[description not available]		02.2110
Arthritis
Acute or chronic inflammation of JOINTS.		02.2110
Multiple Sclerosis
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)		02.2110
Acute Confusional Senile Dementia
[description not available]		03.3310
Alzheimer Disease
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)		03.3310